Clinical Trial Update: To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) [Phase 3]

View source ↗

Summary

Phase 3 LIMBER-304 trial evaluating parsaclisib with ruxolitinib in myelofibrosis patients with suboptimal response to ruxolitinib was terminated, and results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Jakafi (ruxolitinib)
• Parsaclisib (parsaclisib)

Snippet

Sponsor: Incyte Corporation | Conditions: Myelofibrosis, Primary Myelofibrosis | Phase 3 | Status: TERMINATED | Results posted: 2024-08-23